NAMD’s Executive Director Kate McEvoy discusses the impacts of unwinding on Medicaid members and the health care system with the American Journal of Managed Care.
“According to Kaiser Health News,1 many policies that were designed to fight the spread of the virus will end come May 11. For example, vaccines that were previously purchased by the government will remain available for low or no cost as long as the supplies last. However, once that supply runs out, Pfizer has indicated that the prices for the booster will increase to $110 to $130 per dose, which could translate to billions of dollars of revenue for the manufacturers that consumers would be responsible for; Moderna has since announced that its booster will remain free for the time being.
“The signal of the end of the public health emergency starts a process where states will be migrating back to something that looks more like historically typical operations under Medicaid, with the caveat that there are some experiences and approaches that were adopted during the pandemic that will be carried forward,” said Kate McEvoy, executive director of the National Association of Medicaid Directors.
With the ending of the national public health emergency, what does this mean for residents on government-funded health care, and what does this mean for vaccine and treatment access? These questions are important in both the health care and policy sectors and have profound implications for how COVID-19 is addressed going forward.”
You can read the full article here.